Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

New Data and Clinical Perspectives on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

Access Activity

Overview / Abstract:


Prostate cancer is the most common tumor type affecting men in the United States. An estimated 191,930 new cases are diagnosed annually, and 33,330 people die from the disease (ACS, 2020). Most patients with metastatic hormone-sensitive prostate cancer (HSPC) present with relapse after local treatment, while approximately 5% of all prostate cancer patients present with de novo metastatic HSPC (Ng et al, 2020). The five-year overall survival rate for metastatic HSPC remains only 29.8% (Hahn et al, 2018). The treatment of metastatic HSPC has expanded dramatically in recent years with the introduction of several novel therapies. With an array of treatments available, including androgen deprivation therapy (ADT), chemotherapy, and second-generation antiandrogens such as abiraterone, enzalutamide, and apalutamide, clinicians face the challenge of determining the optimal sequencing of therapies for individual patients, with limited data to guide treatment choices (Ng et al, 2020).


Oncologists, urologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with hormone-sensitive prostate cancer (HSPC).


Upon completion of this activity, participants should be able to:

1.) Discuss patient and tumor characteristics that can inform tailored therapeutic approaches for patients with metastatic HSPC
2.) Evaluate emerging data on novel treatment combinations and sequences for patients with metastatic HSPC
3.) Assess strategies to optimize the safety and tolerability of novel therapies for metastatic HSPC


Dec 27, 2021


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Oliver Sartor, MD (Chairperson)
Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research
Tulane University School of Medicine

Activity Specialities / Related Topics

Adverse Drug Reactions / ADR, Diagnosis / Assessment / Patient History, Oncology / Cancer / Radiation Therapy, Radiology / Imagery / Nuclear Medicine, Urology

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Sanofi Genzyme.

Keywords / Search Terms

i3 Health i3 Health, oncology, prostate cancer, urology, hormone-sensitive prostate cancer, HSPC, CME, NCPD, free CME, free NCPD, ILNA points, MOC Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map